The US Food and Drug Administration (FDA) has granted 510(k) clearance to Zimmer Biomet's new revision knee implant component ...

Zimmer Biomet Holdings, Inc. ZBH is participating in the ongoing American Academy of Orthopaedic Surgeons (AAOS) 2025 Annual Meeting in San Diego, from March 10-14. Here, the company is highlighting ...

Zimmer Biomet (NYSE: ZBH) announced today that it received FDA 510(k) clearance for its Persona Revision SoluTion Femur.

For more information about Zimmer Biomet events at AAOS 2025, visit . Important Safety Information for Oxford Cementless Partial Knee: The Oxford® Cementless Partial Knee System is indicated for ...

Zimmer Biomet’s flagship robot, Rosa, is expected to make gains in the near future, CEO Ivan Tornos said at the Barclays 27th Annual Global Healthcare Conference. Mr. Tornos said adoption of the robot ...

Product Portfolio: Launch of the "Magnificent Seven" in reconstructive surgery, including products like Persona Osteotype and Oxford Partial ... knee replacement in the U.S. dropping from 66 to 61.

The US Food and Drug Administration (FDA) has granted 510(k) clearance to Zimmer Biomet's new revision ... fit across primary, partial, and revision knee arthroplasties. Zimmer’s implant is ...

Booth Spotlights Comprehensive Hip Portfolio, Newly Launched Knee and Upper Extremities Reconstructive Technologies, Including Recently Cleared Persona® Revision SoluTion™ Femur, and Debut of ...

along with the latest technologies for knee and upper extremity reconstruction and key components from its robotic solutions. In addition, Zimmer Biomet is debuting ZBX ™, its new Ambulatory ...